EGFR and neoplasm: Additionally, the shRNA-mediated knockdown of LANCL2 reduced proliferation and enhanced apoptosis in the EGFR-mutant LUAD cell lines PC9 and HCC827 in vitro and suppressed PC9 xenograft tumor growth in vivo.